Aquinox Pharma (AQXP) Reports Q3 Loss of $0.46/Share

November 9, 2016 9:17 AM EST
Get Alerts AQXP Hot Sheet
Trade AQXP Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Aquinox Pharma (NASDAQ: AQXP) reported Q3 EPS of ($0.46), versus ($0.43) reported last year.

Cash, cash equivalents, short-term and long-term investments totaled $162.6 million as of September 30, 2016, compared to $112.9 million as of December 31, 2015. The increase was primarily the result of the public offering of common stock in September 2016 partly offset by the ongoing expenditures related to our LEADERSHIP 301 clinical trial in IC/BPS. Aquinox expects its cash, cash equivalents, short-term and long-term investments to be sufficient to complete the LEADERSHIP 301 trial as well as additional clinical development, manufacturing, preclinical, and pre-commercial and market assessment activities.

For earnings history and earnings-related data on Aquinox Pharma (AQXP) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment